FIELD: chemistry.
SUBSTANCE: invention relates to a compound of general formula (I), or a pharmaceutically acceptable salt thereof, wherein ZY is NO or ON; R1 represents a phenyl group, optionally having 1 to 3 substitutes independently selected from the following group A, or a pyridyl group optionally having 1 to 3 substitutes independently selected from the following group A; R2 is -NR21R22, C1-C6 alkyl group, optionally having from 1 to 3 substitutes, independently selected from the following group B, C3-C6 cycloalkyl group, optionally having from 1 to 3 substitutes, independently selected from the following group C, or 4–6 membered heterocyclic group having 1 or 2 heteroatoms independently selected from a group consisting of a nitrogen atom and an oxygen atom in the ring, where 4–6 membered heterocyclic group optionally has from 1 to 3 substitutes independently selected from the next group C, and the bridge structure is optionally bonded within the heterocyclic ring, or one C3-C6 cycloalkyl ring is optionally bonded to a heterocyclic ring through a spiro bond; R21 and R22 each independently represent a hydrogen atom or C1-C6 alkyl group; R3 is any of following formulas (II) - (IV), where R31 is a hydrogen atom, a halogen atom, C1-C6 alkyl group optionally substituted with 1 to 3 halogen atoms, C3-C6 cycloalkyl group or C1-C6 alkylcarbonyl group, R32 is a hydrogen atom or C1-C6 alkyl group, or R31 and R32 optionally together form a cyclohexane ring, R33 is a hydrogen atom or C1-C6 alkyl group, or R32 and R33 optionally together form cyclopropane ring, R34 is a hydrogen atom, R35 is C1-C6 alkyl group, R36 is a hydrogen atom, R37 represents a hydrogen atom, or R36 and R37 optionally together form a benzene ring, R38 is a hydrogen atom or a halogen atom, X and W represent a nitrogen atom or CH, and the dashed line represents a single bond or a double bond; group A consists of a halogen atom, C1-C6 alkyl group and C1-C6 alkoxy group; group B consists of a halogen atom, a hydroxyl group, C1-C6 alkoxy group, C1-C6 alkylamino groups and di-C1-C6 alkylamino groups, group C consists of C2-C6 alkenyl group, halogen atom, hydroxyl group, cyano group, C1-C6 alkyl group, optionally having from 1 to 3 substitutes, independently selected from the following group D, C1-C6 alkoxy group, -NR211R212, -C(=O)R213 and -SO2R213; R211 and R212 each independently represents a hydrogen atom or C1-C6 alkyl group; R213 is C2-C6 alkenyl group or C2-C6 alkynyl group; and group D consists of amino group, C1-C6 alkoxy group, di-C1-C6 alkylamino groups, oxo groups and C3-C6 cycloalkyl group. Invention also relates to specific compounds given in the patent claim.
,
.
EFFECT: compounds of the invention are intended as an inhibitor of mutant isocitrate dehydrogenase 1 and a product inhibitor D-2-hydroxyglutarate.
22 cl, 93 tbl, 4 dwg, 183 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRIAZOLE COMPOUNDS OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND ANTIFUNGAL COMPOSITION | 1996 |
|
RU2146250C1 |
| PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | 2014 |
|
RU2663898C2 |
| 2-PYRIDONE DERIVATIVES | 2010 |
|
RU2551847C2 |
| IMIDAZOPYRIDIN-2-ONE DERIVATIVES, HAVING mTOR INHIBITING ACTIVITY | 2009 |
|
RU2478636C2 |
| PESTICIDAL COMPOSITIONS AND METHODS RELATED THERETO | 2013 |
|
RU2667788C2 |
| CRYSTALLINE FORMS OF DIAZABICLOCTANE DERIVATIVE AND A METHOD OF THEIR PRODUCTION | 2014 |
|
RU2801220C2 |
| NEW COMPOUND, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2814103C1 |
| CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND METHOD FOR PRODUCTION THEREOF | 2014 |
|
RU2695219C2 |
| GRISEOFULVIN COMPOUND | 2017 |
|
RU2736208C2 |
| NEW COMPOUNDS AND COMPOSITIONS FOR CATHEPSIN INHIBITION | 2004 |
|
RU2346943C2 |
